100.02
Zimmer Biomet Holdings Inc stock is traded at $100.02, with a volume of 1.84M.
It is up +0.77% in the last 24 hours and up +6.64% over the past month.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
See More
Previous Close:
$99.26
Open:
$99.54
24h Volume:
1.84M
Relative Volume:
0.87
Market Cap:
$19.81B
Revenue:
$7.68B
Net Income/Loss:
$903.80M
P/E Ratio:
22.48
EPS:
4.45
Net Cash Flow:
$1.14B
1W Performance:
+8.25%
1M Performance:
+6.64%
6M Performance:
+1.05%
1Y Performance:
-7.46%
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Name
Zimmer Biomet Holdings Inc
Sector
Industry
Phone
(574) 267-6131
Address
345 EAST MAIN STREET, WARSAW, IN
Compare ZBH with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ZBH
Zimmer Biomet Holdings Inc
|
100.02 | 19.66B | 7.68B | 903.80M | 1.14B | 4.45 |
![]()
ABT
Abbott Laboratories
|
131.36 | 233.71B | 43.11B | 13.98B | 6.78B | 7.98 |
![]()
BSX
Boston Scientific Corp
|
102.75 | 152.83B | 18.49B | 2.51B | 3.23B | 1.68 |
![]()
SYK
Stryker Corp
|
376.67 | 144.35B | 23.82B | 2.92B | 4.02B | 7.55 |
![]()
MDT
Medtronic Plc
|
92.74 | 119.00B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
78.16 | 46.00B | 5.69B | 4.14B | 577.90M | 6.96 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-15-25 | Upgrade | Roth Capital | Neutral → Buy |
Dec-17-24 | Upgrade | JP Morgan | Neutral → Overweight |
Sep-10-24 | Initiated | Wolfe Research | Peer Perform |
Jul-01-24 | Downgrade | Piper Sandler | Overweight → Neutral |
May-30-24 | Initiated | Goldman | Neutral |
May-21-24 | Upgrade | Argus | Hold → Buy |
Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
Oct-20-23 | Initiated | ROTH MKM | Neutral |
Aug-28-23 | Upgrade | BTIG Research | Neutral → Buy |
May-03-23 | Upgrade | BofA Securities | Underperform → Neutral |
Apr-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
Mar-31-23 | Upgrade | Jefferies | Underperform → Hold |
Mar-29-23 | Initiated | UBS | Sell |
Mar-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Jan-09-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Jan-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jan-03-23 | Downgrade | Evercore ISI | Outperform → In-line |
Nov-23-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Oct-18-22 | Initiated | Barclays | Underweight |
Oct-12-22 | Initiated | Jefferies | Underperform |
May-27-22 | Downgrade | Needham | Buy → Hold |
Apr-13-22 | Downgrade | Truist | Buy → Hold |
Apr-01-22 | Downgrade | Citigroup | Buy → Neutral |
Mar-02-22 | Resumed | BofA Securities | Underperform |
Mar-02-22 | Downgrade | Loop Capital | Buy → Hold |
Feb-08-22 | Downgrade | Canaccord Genuity | Buy → Hold |
Feb-08-22 | Reiterated | Citigroup | Buy |
Feb-08-22 | Reiterated | Deutsche Bank | Hold |
Feb-08-22 | Reiterated | JMP Securities | Mkt Outperform |
Feb-08-22 | Reiterated | JP Morgan | Neutral |
Feb-08-22 | Reiterated | RBC Capital Mkts | Sector Perform |
Feb-08-22 | Reiterated | Stifel | Buy |
Feb-08-22 | Reiterated | Truist | Buy |
Feb-08-22 | Reiterated | UBS | Neutral |
Feb-08-22 | Reiterated | Wells Fargo | Underweight |
Feb-02-22 | Downgrade | UBS | Buy → Neutral |
Jan-19-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
Jan-10-22 | Downgrade | Mizuho | Buy → Neutral |
Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jan-04-22 | Downgrade | Piper Sandler | Overweight → Neutral |
Dec-10-21 | Initiated | RBC Capital Mkts | Sector Perform |
Dec-09-21 | Downgrade | Needham | Strong Buy → Buy |
Dec-07-21 | Initiated | Loop Capital | Buy |
Nov-23-21 | Downgrade | Argus | Buy → Hold |
Sep-14-21 | Resumed | Raymond James | Mkt Perform |
May-25-21 | Initiated | Barclays | Overweight |
Apr-09-21 | Upgrade | Northland Capital | Market Perform → Outperform |
Jan-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
Dec-18-20 | Reiterated | Needham | Strong Buy |
Oct-20-20 | Initiated | Northland Capital | Market Perform |
Sep-11-20 | Initiated | Wolfe Research | Outperform |
Aug-05-20 | Reiterated | Needham | Strong Buy |
Apr-28-20 | Downgrade | Guggenheim | Buy → Neutral |
Apr-09-20 | Downgrade | Evercore ISI | Outperform → In-line |
Apr-07-20 | Reiterated | Needham | Strong Buy |
Mar-05-20 | Initiated | Citigroup | Buy |
Feb-13-20 | Initiated | Goldman | Buy |
Jan-08-20 | Initiated | SunTrust | Buy |
Jan-07-20 | Upgrade | Piper Jaffray | Neutral → Overweight |
Jan-07-20 | Upgrade | Piper Sandler | Neutral → Overweight |
Dec-04-19 | Upgrade | Raymond James | Outperform → Strong Buy |
Oct-07-19 | Upgrade | BTIG Research | Neutral → Buy |
Sep-18-19 | Upgrade | Canaccord Genuity | Hold → Buy |
Aug-12-19 | Upgrade | Argus | Hold → Buy |
Jul-30-19 | Upgrade | Barclays | Underweight → Equal Weight |
Jul-29-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
Jun-11-19 | Upgrade | Bernstein | Underperform → Mkt Perform |
Apr-24-19 | Upgrade | Needham | Buy → Strong Buy |
View All
Zimmer Biomet Holdings Inc Stock (ZBH) Latest News
Needham Maintains a Neutral Stance on Zimmer Biomet Holdings (ZBH) - MSN
Zimmer (ZBH) Builds Robotics Growth Pipeline, but BofA Sees Limited Near-Term Upside - MSN
Zimmer Biomet (ZBH) Jumps After Raising 2025 Outlook on Strong Hip and Knee Sales—Is Momentum Sustainable? - simplywall.st
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q2 2025 Earnings Call Transcript - MSN
Healthcare Sector Analysts Weigh In on Sangamo Biosciences, Pliant Therapeutics, and Zimmer Biomet Holdings - AInvest
What You Need To Know Ahead of Zimmer Biomet's Earnings Release - MSN
Zimmer Biomet Acquires Monogram Technologies, Boosting Robotics Growth Pipeline, but BofA Sees Limited Near-Term Upside - AInvest
While shareholders of Zimmer Biomet Holdings (NYSE:ZBH) are in the red over the last five years, underlying earnings have actually grown - simplywall.st
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day - MSN
Zimmer Biomet Holdings Maintains Hold Rating Amid Volatility Concerns - AInvest
Zimmer Biomet Surges Despite 404th-Ranked Liquidity as Earnings Outperform and UBS Maintains Sell Rating - AInvest
RBC Capital Raises Zimmer Biomet PT to $115, Maintains Outperform Rating - AInvest
UBS maintains Sell rating, raises Zimmer Biomet PT to $96 from $91. - AInvest
Morgan Stanley Raises Price Target on Zimmer Biomet to $100 From $95 - MarketScreener
Raymond James maintains Outperform rating on Zimmer Biomet with new PT of $113. - AInvest
Zimmer Biomet Holdings, Inc. shares fall 1.09% intraday as brokerages adjust price targets and global growth concerns persist. - AInvest
RBC Raises Price Target on Zimmer Biomet Holdings to $115 From $112, Keeps Outperform Rating - MarketScreener
Zimmer Biomet price target raised to $113 from $104 at Raymond James - TipRanks
UBS Hikes Price Target on Zimmer Biomet to $96 From $91, Maintains Sell Rating - MarketScreener
Bernstein raises Zimmer Biomet stock price target to $105 on improving outlook - Investing.com Canada
Zimmer Biomet Boosts 2025 Outlook on Strong Portfolio Growth and Reduced Tariff Impacts - AInvest
Zimmer Biomet price target raised to $96 from $91 at UBS - TipRanks
Zimmer Biomet raises 2025 outlook amid strong portfolio growth - Yahoo Finance
Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - Yahoo Finance
Zimmer Biomet Holdings: Balancing Strong Segment Growth with US Knee Challenges – Hold Rating Maintained - TipRanks
Zimmer Biomet Q2 2025 net sales up 7% to USD 2.077B - Medical Buyer
Jefferies Adjusts Price Target on Zimmer Biomet to $110 From $103, Maintains Hold Rating - MarketScreener
Bernstein Adjusts Price Target on Zimmer Biomet to $105 From $100, Maintains Market Perform Rating - MarketScreener
JPMorgan Adjusts Price Target on Zimmer Biomet to $115 From $105, Maintains Overweight Rating - MarketScreener
Spinal Fusion Devices Market Outlook Report 2025-2029: Revenues to Grow by $2.9 Billion Driven by Rising Spinal Disorders, Technological Advances, and Increasing Device Launches - GlobeNewswire Inc.
Zimmer: Q2 Earnings Snapshot - Connecticut Post
Zimmer Biomet Reports Strong Q2 2025 Results - TipRanks
Zimmer Biomet Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Zimmer Biomet Surges 7.99% on Revised Earnings and Tariff Relief Ranks 287th in $420M Volume - AInvest
Zimmer Biomet Reports Q2 Earnings, Raises Full-Year Outlook - InkFreeNews.com
Zimmer Biomet Holdings: Hold Rating Maintained Amid Stable Growth and Second-Half Optimism - TipRanks
Zimmer Biomet raises annual profit forecast on strong demand for medical devices - WKZO
Zimmer Biomet Holdings: Hold Rating Maintained Amid Modest Growth and Market Shifts - TipRanks
Zimmer Biomet price target raised to $138 from $135 at Roth Capital - TipRanks
Zimmer Biomet Exceeds Q2 Expectations with 7% YoY Revenue Growth - AInvest
Zimmer Biomet (NYSE:ZBH) Exceeds Q2 Expectations, Stock Soars - Yahoo Finance
Zimmer Biomet raises annual profit forecast on lower tariff impact - MSN
ZBH Stock Gains On Q2 Earnings and Revenue Beat, '25 EPS View Up - The Globe and Mail
Zimmer Biomet Flexes Strong Q2, Raises 2025 OutlookZimmer Biomet Holdings (NYSE:ZBH) - Benzinga
Zimmer Biomet posts Q2 beats, raises EPS guidance - MassDevice
Transcript : Zimmer Biomet Holdings, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Zimmer Biomet Holdings Shares Surge Amid Strong Q2 - TipRanks
Zimmer (ZBH) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Zimmer Biomet Lifts Forecast As Joint Implant Sales Climb - Finimize
Zimmer Biomet (ZBH) Beats Q2 Earnings and Revenue Estimates - sg.finance.yahoo.com
Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2025 - MarketScreener
Zimmer Biomet Holdings Inc Stock (ZBH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zimmer Biomet Holdings Inc Stock (ZBH) Insider Trading
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):